Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $177.0 million.

  • Kiniksa Pharmaceuticals International's Total Liabilities rose 4958.75% to $177.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.0 million, marking a year-over-year increase of 4958.75%. This contributed to the annual value of $142.1 million for FY2024, which is 6245.1% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Total Liabilities stood at $177.0 million for Q3 2025, which was up 4958.75% from $166.1 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Total Liabilities registered a high of $177.0 million during Q3 2025, and its lowest value of $38.8 million during Q3 2021.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Total Liabilities had a median value of $75.9 million in 2022 and averaged $87.5 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Total Liabilities soared by 9567.91% in 2022, and later tumbled by 1847.0% in 2023.
  • Kiniksa Pharmaceuticals International's Total Liabilities (Quarter) stood at $47.8 million in 2021, then soared by 33.0% to $63.5 million in 2022, then surged by 37.72% to $87.5 million in 2023, then surged by 62.45% to $142.1 million in 2024, then increased by 24.51% to $177.0 million in 2025.
  • Its Total Liabilities was $177.0 million in Q3 2025, compared to $166.1 million in Q2 2025 and $141.8 million in Q1 2025.